Li Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Li Jiang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Alvaro Munoz
Department of Welfare and Sustainable Development, Centro Universitario del Norte, Universidad de Guadalajara, Colotlan, Jalisco, Mexico
1 shared publicationChengyu Zhou
Department of Rehabilitation Medicine, The third Xiangya Hospital, Central South University Third Xiangya Hospital, Changsha, 410013, China
1 shared publicationChuanna Liu
Department of Rehabilitation Medicine, the Third Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China
1 shared publicationJianda Zhou
Department of Plastic Surgery, Third Xiangya Hospital, Central South University, Changsha 410000, PR China
1 shared publicationJiaqi Zhang
Department of Rehabilitation Medicine, Third Xiangya Hospital, Central South University, Changsha 410000, PR China
1 shared publicationKe Shi
Department of Plastic Surgery, Third Xiangya Hospital, Central South University, Changsha 410000, PR China
1 shared publication
Latest Publications
- Open Access
- 29 April 2026
- Published by Springer Nature in Lasers in Medical Science
- Vol. 41 (1)
Collagen remodeling drives continence recovery: radiofrequency therapy ameliorates SUI via TGF-β1/Smad2 pathway activation – evidence from a rat model
Proposed Mechanism of Radiofrequency (RF) Therapy for Stress Urinary Incontinence (SUI). Vaginal RF treatment delivers controlled thermal energy to the tissue. This stimulus is proposed to activate transforming growth factor-beta (TGF-β) signaling. TGF-β binding to its receptor leads to phosphorylation of Smad2 (P-Smad2) and its translocation into the nucleus. Within the nucleus, the activated Smad complex regulates gene expression, promoting the synthesis of type III collagen while inhibiting degradation pathways. This restoration of collagen architecture strengthens pelvic floor support, thereby improving urethral closure function and alleviating SUI. Created with BioRender.com The online version contains supplementary material available at 10.1007/s10103-026-04879-4.
- 29 April 2026
- Published by Springer Nature in Lasers in Medical Science
- Vol. 41 (1)
Open AccessCollagen remodeling drives continence recovery: radiofrequency therapy ameliorates SUI via TGF-β1/Smad2 pathway activation – evidence from a rat model
Proposed Mechanism of Radiofrequency (RF) Therapy for Stress Urinary Incontinence (SUI). Vaginal RF treatment delivers controlled thermal energy to the tissue. This stimulus is proposed to activate transforming growth factor-beta (TGF-β) signaling. TGF-β binding to its receptor leads to phosphorylation of Smad2 (P-Smad2) and its translocation into the nucleus. Within the nucleus, the activated Smad complex regulates gene expression, promoting the synthesis of type III collagen while inhibiting degradation pathways. This restoration of collagen architecture strengthens pelvic floor support, thereby improving urethral closure function and alleviating SUI. Created with BioRender.com The online version contains supplementary material available at 10.1007/s10103-026-04879-4.
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 18, 1-14
Ectopic Pregnancy Mortality Trends in BRICS: Age-Period-Cohort Analysis of Global Burden Disease 2021 Data and 2030 Forecast
Purpose: Ectopic pregnancy (EP) is a significant contributor to maternal mortality, posing a major burden on women in developing countries. This study examined global trends in EP mortality from 1982 to 2021, focusing on developing nations represented by BRICS countries (Brazil, Russian Federation, India, China, and South Africa). Methods: Based on the Global Burden Disease (GBD) 2021, an analysis of EP mortality was conducted by location (global and BRICS), age group (15– 49 years), and years (1982– 2021). The age-period-cohort (APC) model was utilized to estimate net drift, local drift, age effects, period effects, and cohort effects from 1982 to 2021. Furthermore, the Autoregressive Integrated Moving Average (ARIMA) model was employed to forecast EP mortality from 2022 to 2030. Results: Globally, the number of deaths due to EP reached 6442 (95% CI: 5368 to 7796) in 2021, representing a 55.08% increase compared with 1982. Despite rising absolute deaths, the global Age-Standardized Mortality Rate (ASMR) declined by 15.79%, reaching 0.16 per 100,000 population in 2021 (95% UI: 0.14 to 0.20), indicating a reduction in population-level risk after accounting for demographic structure. EP mortality predominantly affected individuals aged 20– 39 years across regions. APC analyses revealed distinct period and cohort effects, with marked heterogeneity across BRICS countries. Net Drift estimates ranged from a substantial annual decline in the Russian Federation (− 10.12%) to a modest decrease in India (− 1.62%), with Brazil, China, and South Africa showing intermediate downward trends. Conclusion: From 1982 to 2021, varying advancements in managing EP were observed among BRICS nations. Tailored financial allocations and policy measures aided in lowering EP mortality. Enhancing cross-country collaboration and knowledge exchange within BRICS countries is crucial for further ameliorating EP outcomes.
- 1 March 2026
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 18, 1-14
Open AccessEctopic Pregnancy Mortality Trends in BRICS: Age-Period-Cohort Analysis of Global Burden Disease 2021 Data and 2030 Forecast
Purpose: Ectopic pregnancy (EP) is a significant contributor to maternal mortality, posing a major burden on women in developing countries. This study examined global trends in EP mortality from 1982 to 2021, focusing on developing nations represented by BRICS countries (Brazil, Russian Federation, India, China, and South Africa). Methods: Based on the Global Burden Disease (GBD) 2021, an analysis of EP mortality was conducted by location (global and BRICS), age group (15– 49 years), and years (1982– 2021). The age-period-cohort (APC) model was utilized to estimate net drift, local drift, age effects, period effects, and cohort effects from 1982 to 2021. Furthermore, the Autoregressive Integrated Moving Average (ARIMA) model was employed to forecast EP mortality from 2022 to 2030. Results: Globally, the number of deaths due to EP reached 6442 (95% CI: 5368 to 7796) in 2021, representing a 55.08% increase compared with 1982. Despite rising absolute deaths, the global Age-Standardized Mortality Rate (ASMR) declined by 15.79%, reaching 0.16 per 100,000 population in 2021 (95% UI: 0.14 to 0.20), indicating a reduction in population-level risk after accounting for demographic structure. EP mortality predominantly affected individuals aged 20– 39 years across regions. APC analyses revealed distinct period and cohort effects, with marked heterogeneity across BRICS countries. Net Drift estimates ranged from a substantial annual decline in the Russian Federation (− 10.12%) to a modest decrease in India (− 1.62%), with Brazil, China, and South Africa showing intermediate downward trends. Conclusion: From 1982 to 2021, varying advancements in managing EP were observed among BRICS nations. Tailored financial allocations and policy measures aided in lowering EP mortality. Enhancing cross-country collaboration and knowledge exchange within BRICS countries is crucial for further ameliorating EP outcomes.
- 22 November 2023
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1870 (2) , 166965
Pan-cancer analysis of PLAU indicates its potential prognostic value and correlation with neutrophil infiltration in BLCA
- 22 November 2023
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1870 (2) , 166965
Pan-cancer analysis of PLAU indicates its potential prognostic value and correlation with neutrophil infiltration in BLCA
- 26 January 2021
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (1) , 146-158
Hydroxysteroid 17-Beta Dehydrogenase 6 Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma
Background Hepatocellular carcinoma (HCC) is a common malignancy worldwide with poor outcomes. Therefore, it is important to identify a valuable prognostic biomarker for HCC. The present study aimed to identify novel prognostic biomarkers for HCC and evaluate the potential role of hub genes in HCC. Methods Weighted gene co-expression network analysis and protein–protein interaction analysis were performed to identify important potential prognostic genes. The expression of hub genes was confirmed by the GEPIA, Oncomine, UALCAN, and HPA database. Furthermore, survival analysis of hub genes was performed using the Kaplan–Meier plotter database. Finally, we investigated the association between hub genes and immune factors in HCC through GSEA, the TIMER, and TISIDB database. Results HSD17B6 expression was significantly lower in HCC than in normal tissues. Low HSD17B6 expression is associated with poorer overall survival and progression-free survival in HCC patients, particularly at medium disease stages (stage II and III or grade III). HSD17B6 showed a strong correlation with tumor-infiltrating B cells, CD4 + and CD8 + T cells, macrophages, neutrophils, and dendritic cells. Somatic copy number alteration might be the main cause of the negative correlation between HSD17B6 expression and immune infiltration. HSD17B6 expression in HCC negatively correlated with the expression of several immune cell markers, including exhausted T cell markers, PD-1 and CTLA-4, suggesting its role in regulating tumor immunity. Conclusions HSD17B6 is a potential prognostic biomarker that determines cancer progression and is correlated with tumor immune cells infiltration in HCC.
- 26 January 2021
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (1) , 146-158
Hydroxysteroid 17-Beta Dehydrogenase 6 Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma
Background Hepatocellular carcinoma (HCC) is a common malignancy worldwide with poor outcomes. Therefore, it is important to identify a valuable prognostic biomarker for HCC. The present study aimed to identify novel prognostic biomarkers for HCC and evaluate the potential role of hub genes in HCC. Methods Weighted gene co-expression network analysis and protein–protein interaction analysis were performed to identify important potential prognostic genes. The expression of hub genes was confirmed by the GEPIA, Oncomine, UALCAN, and HPA database. Furthermore, survival analysis of hub genes was performed using the Kaplan–Meier plotter database. Finally, we investigated the association between hub genes and immune factors in HCC through GSEA, the TIMER, and TISIDB database. Results HSD17B6 expression was significantly lower in HCC than in normal tissues. Low HSD17B6 expression is associated with poorer overall survival and progression-free survival in HCC patients, particularly at medium disease stages (stage II and III or grade III). HSD17B6 showed a strong correlation with tumor-infiltrating B cells, CD4 + and CD8 + T cells, macrophages, neutrophils, and dendritic cells. Somatic copy number alteration might be the main cause of the negative correlation between HSD17B6 expression and immune infiltration. HSD17B6 expression in HCC negatively correlated with the expression of several immune cell markers, including exhausted T cell markers, PD-1 and CTLA-4, suggesting its role in regulating tumor immunity. Conclusions HSD17B6 is a potential prognostic biomarker that determines cancer progression and is correlated with tumor immune cells infiltration in HCC.